论文部分内容阅读
目的系统评价格拉斯哥预后评分(Glasgow Prognostic Score,GPS)对肝细胞肝癌患者预后的影响。方法检索Pub Med(Medline),Embase,Cochrane Library,Web of Science,万方数据和中国知网中的相关文献(自建库至2015年9月),针对GPS与肝细胞肝癌患者预后的关系进行荟萃分析。结果经过严格筛选,共纳入10篇相关文献。荟萃分析提示高GPS评分的肝细胞肝癌患者的总生存期较低GPS评分者总生存期短(HR:2.156,95%CI:1.696~2.740,P<0.001)。高GPS评分的肝细胞肝癌患者大多Child–Pugh分级较高[odds ratio(OR)=25.979,95%CI:6.159~109.573,P<0.001]。本荟萃分析发表偏倚显著。结论 GPS可能是肝细胞肝癌患者的预后指标,其预后价值也需更多严格设计的临床研究加以巩固证实。
Objective To systematically evaluate the effect of Glasgow Prognostic Score (GPS) on the prognosis of patients with hepatocellular carcinoma. Methods Search Pub Med (Medline), Embase, Cochrane Library, Web of Science, Wanfang Data and related articles in China Knowledge Network (self-built database up to September 2015), to investigate the relationship between GPS and prognosis of patients with hepatocellular carcinoma. Meta-analysis. After strict screening, a total of 10 related articles were included. Meta-analysis suggests that the overall survival of patients with high GPS-rated hepatocellular carcinoma is low. The overall survival time of GPS-graders is short (HR: 2.156, 95% CI: 1.696-2.740, P<0.001). Most patients with hepatocellular carcinoma with high GPS scores had a high Child-Pugh score (odds ratio (OR) = 25.979, 95% CI: 6.159~109.573, P<0.001). This meta-analysis reveals a significant bias in publication. Conclusion GPS may be a prognostic indicator for patients with hepatocellular carcinoma, and its prognostic value needs to be confirmed by more rigorously designed clinical studies.